The AstraZeneca PLC ADR AZN rose 1.79% to $75.57 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite Index COMP rising 1.22% to ...

Treatments for autoimmune diseases and those in orphan markets are on the up and up, as are drugmakers’ first launches, ...

The deal gives the Swiss pharma access to an experimental amylin-targeting treatment it will test in combination with drugs ...

Montgomery College has received approval from the Maryland Apprenticeship and Training Council (MATC) to become a sponsor of ...

Arvinas stock plummets 53% on mixed data from phase III metastatic breast cancer study on lead pipeline candidate, vepdegestrant.

Astrazeneca (AZN) ended the recent trading session at $75.57, demonstrating a +1.79% swing from the preceding day's closing price. This change outpaced the S&P 500's 0.49% gain on the day. On the ...

The National Institutes of Health, which falls under the jurisdiction of HHS, has terminated grants for research into vaccine hesitancy, according to the Washington Post, even though the Texas measles ...

Introduction Vaccines are biological preparations that stimulate the immune system to develop protection against specific infectious diseases.

Industries minister TRB Rajaa bats for 'Making in Tamil Nadu for world', says state's manufacturing talent pool on a par with ...

The agreement covering the compound petrelintide, announced by Roche on Wednesday, marks renewed efforts to catch up with weight-loss market leaders Novo Nordisk and Eli Lilly .

Roche and Zealand Pharma inked a $5.3 billion deal Wednesday to collaborate on a weight-loss drug in the amylin class.